NO20004098L - FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser - Google Patents

FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser

Info

Publication number
NO20004098L
NO20004098L NO20004098A NO20004098A NO20004098L NO 20004098 L NO20004098 L NO 20004098L NO 20004098 A NO20004098 A NO 20004098A NO 20004098 A NO20004098 A NO 20004098A NO 20004098 L NO20004098 L NO 20004098L
Authority
NO
Norway
Prior art keywords
macrophage
preparations
treatment
methods
mediated disorders
Prior art date
Application number
NO20004098A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004098D0 (no
Inventor
Jan G J Van De Winkel
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of NO20004098D0 publication Critical patent/NO20004098D0/no
Publication of NO20004098L publication Critical patent/NO20004098L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
NO20004098A 1998-02-17 2000-08-16 FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser NO20004098L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7496798P 1998-02-17 1998-02-17
PCT/US1999/003488 WO1999041285A1 (en) 1998-02-17 1999-02-17 Treating and diagnosing macrophage-mediated diseases using fc receptor ligands

Publications (2)

Publication Number Publication Date
NO20004098D0 NO20004098D0 (no) 2000-08-16
NO20004098L true NO20004098L (no) 2000-10-02

Family

ID=22122724

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004098A NO20004098L (no) 1998-02-17 2000-08-16 FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser

Country Status (15)

Country Link
US (2) US20020058284A1 (ko)
EP (1) EP1056781A1 (ko)
JP (1) JP2002503676A (ko)
KR (1) KR20010041010A (ko)
CN (1) CN1307590A (ko)
AU (1) AU2772199A (ko)
CA (1) CA2321136A1 (ko)
EA (1) EA200000848A1 (ko)
HK (1) HK1038931A1 (ko)
HU (1) HUP0100929A3 (ko)
IL (1) IL137919A0 (ko)
NO (1) NO20004098L (ko)
PL (1) PL342729A1 (ko)
SI (1) SI20475A (ko)
WO (1) WO1999041285A1 (ko)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756396B1 (en) * 1997-05-07 2004-06-29 Qlt Inc. Ethylene glycol esters as photoactive agents
KR20040015234A (ko) 2001-05-02 2004-02-18 펄듀 리서치 파운데이션 대식세포 매개된 질환의 치료와 진단
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US7425619B2 (en) 2002-08-14 2008-09-16 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
WO2007094776A1 (en) * 2006-02-15 2007-08-23 William Marsh Rice University Compositions and methods for suppressing fibrocyte differentiation
ES2318195T3 (es) 2002-12-23 2009-05-01 William Marsh Rice University Metodos y composiciones para potenciar la formacion de fibrocitos.
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
US20100297074A1 (en) * 2002-12-23 2010-11-25 Richard Hans Gomer Wound healing compositions, systems, and methods
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2524441C (en) * 2003-05-06 2012-03-20 Purdue Research Foundation Treatment of lupus targeting the macrophages or the folate receptor
US20050008633A1 (en) * 2003-05-19 2005-01-13 Advanced Inhalation Research Inc. Chemical and physical modulators of bioavailability of inhaled compositions
BG65715B1 (bg) * 2003-09-04 2009-08-31 Чавдар ВАСИЛЕВ Средство за селективно подтискане на патологични днк - специфични в клетки
US7057624B2 (en) * 2003-10-28 2006-06-06 Eastman Kodak Company Display device light leakage compensation
EP1570858A1 (en) * 2004-03-05 2005-09-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Monovalent ligand of the FCalphaRi receptor as an anti-inflammatory agent
WO2005110474A2 (en) 2004-05-10 2005-11-24 Macrogenics, Inc. HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2006060664A2 (en) * 2004-12-03 2006-06-08 The Uab Research Foundation Single-drug multi-ligand conjugates for targeted drug delivery
US20060128031A1 (en) * 2004-12-15 2006-06-15 Robotti Karla M Addressable recovery of bound analytes from an evanescent wave sensor
US20070009434A1 (en) * 2005-07-05 2007-01-11 Low Philip S Imaging and therapeutic method using monocytes
WO2007038346A2 (en) 2005-09-23 2007-04-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
ES2489646T3 (es) 2006-05-26 2014-09-02 Macrogenics, Inc. Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
PL2029173T3 (pl) 2006-06-26 2017-04-28 Macrogenics, Inc. Przeciwciała swoiste dla FC RIIB i sposoby ich zastosowania
US8685752B2 (en) 2006-11-03 2014-04-01 Purdue Research Foundation Ex vivo flow cytometry method and device
AU2007328206B2 (en) * 2006-12-04 2013-08-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
US8586595B2 (en) 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
WO2008148001A2 (en) 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
JP5555223B2 (ja) 2008-04-02 2014-07-23 マクロジェニクス，インコーポレーテッド ＨＥＲ２／ｎｅｕ特異的抗体およびその使用方法
EP2252631B1 (en) 2008-04-02 2016-04-13 MacroGenics, Inc. Bcr-complex-specific antibodies and methods of using same
DK2405928T3 (en) 2009-03-11 2017-01-30 Promedior Inc Treatment and diagnosis procedure for hypersensitive diseases
ES2684493T3 (es) 2009-03-11 2018-10-03 Promedior Inc. Un polipéptido SAP para uso en el tratamiento de trastornos autoinmunitarios y enfermedad del injerto contra el huésped
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
US8329659B2 (en) 2009-06-17 2012-12-11 Promedior, Inc. SAP variants and their use
CA2770771C (en) 2009-08-10 2019-12-03 Jose Procopio Moreno Senna Monoclonal antibodies for pbp2-a protein and homologous sequences for treatment of infections and immunodiagnosis on bacteria from phylum firmicutes
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
KR102006997B1 (ko) * 2012-07-03 2019-08-02 한국생명공학연구원 ＩｇＧ Ｆｃ 위치선택적 결합 펩티드 및 이를 포함하는 하이브리드 분자
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
KR102514317B1 (ko) 2016-04-15 2023-03-27 마크로제닉스, 인크. 신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법
CN109490540A (zh) * 2017-09-13 2019-03-19 中国科学院上海药物研究所 单核/巨噬细胞在主动脉损伤中的诊断和治疗应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4470925A (en) * 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5635600A (en) * 1986-07-07 1997-06-03 Trustees Of Dartmouth College Bifunctional and heteroantibodies specific for the high affinity Fc receptor for immunoglobulin G on human mononuclear phagocytes
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4869903A (en) * 1987-05-29 1989-09-26 Genelabs Incorporated Method of selectively inhibiting HIV
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
US5840840A (en) * 1990-04-17 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Selective RNase cytotoxic reagents
US5767106A (en) * 1992-02-21 1998-06-16 Hyal Pharmaceutical Corporation Treatment of disease and conditions associated with macrophage infiltration
US5686072A (en) * 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5489525A (en) * 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
IL111105A (en) * 1993-09-30 2009-05-04 Univ Pennsylvania Use of a molecule capable of inhibiting the expression of syk kinase to prepare a pharmaceutical composition for inhibiting phagocytosis
US5578706A (en) * 1993-11-04 1996-11-26 Board Of Regents, The University Of Texas Methods and compositions concerning homogenous immunotoxin preparations
US5580715A (en) * 1994-08-05 1996-12-03 The Regents Of The University Of California Diagnosis of cancer having clonal macrophage involvement
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
EP0929300B1 (en) * 1996-09-06 2004-05-26 Medarex, Inc. Cyanidin compositions and therapeutic and diagnostic uses therefor

Also Published As

Publication number Publication date
KR20010041010A (ko) 2001-05-15
EP1056781A1 (en) 2000-12-06
IL137919A0 (en) 2001-10-31
HK1038931A1 (zh) 2002-04-04
PL342729A1 (en) 2001-07-02
CN1307590A (zh) 2001-08-08
JP2002503676A (ja) 2002-02-05
US20020058284A1 (en) 2002-05-16
CA2321136A1 (en) 1999-08-19
US20040141967A1 (en) 2004-07-22
HUP0100929A3 (en) 2005-10-28
AU2772199A (en) 1999-08-30
SI20475A (sl) 2001-08-31
EA200000848A1 (ru) 2001-04-23
NO20004098D0 (no) 2000-08-16
HUP0100929A2 (hu) 2001-06-28
WO1999041285A1 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
NO20004098L (no) FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
NO972972D0 (no) Sammensetninger for behandling av dermatologiske forstyrrelser og metoder for deres anvendelse
NO994613D0 (no) Fremgangsmaate og preparat til behandling av sövn-apne
NO20001754D0 (no) Prostaglandinagonister og anvendelse derav for behandling av benforstyrrelser
NO971015D0 (no) Forbindelser og metoder for behandling av cancer
NO994778D0 (no) FremgangsmÕter og sammensetninger for behandling av tarmbetennelse
NO996483L (no) Imidasopyrimidiner og imidasopyridiner for behandling av neurologiske lidelser
IS5500A (is) Lyfjablöndur til öftrunar og meðferðar mýlildi ogtengdum sjúkdómum
NO994014D0 (no) Arylsulfonamider og analoger derav og deres anvendelse for behandling av neurodegenerative sykdommer
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE69825447D1 (de) Gerät zur dermatologischen behandlung
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
NO985484D0 (no) FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi
NO20015542L (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
NO20012963L (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
NO20001412D0 (no) Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
NO20003229L (no) Kombinasjon av benzosykloheptapyridinforbindelser og antineoplastiske midler for behandling av proliferaktive sykdommer
NO983512D0 (no) Midler for behandling og forhindring av AIDS
EP1030663A4 (en) TREATMENT OF FIBROMYALGIA AND RELATED DISEASES
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
NO20010464L (no) FremgangsmÕter og preparater for behandling av gastro- øsofagealt-reflukssyndrom
NO20001758D0 (no) Fremgangsmåter og blandinger for behandling av leddgikt
NO973193D0 (no) Kollagen-baserte metoder og formuleringer for behandling av immune system-medierte sykdommer
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application